Rapid Evidence-Based Evaluation of Drug Therapy for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children

Zhou Pengxiang; Zhou Wei; Liu Ling; Zhang Yahui; Yang Li

doi:10.13407/ j.cnki.jpp.1672.108X.2020.04.007

您当前的位置：

首页 >

文章列表页 >

Rapid Evidence-Based Evaluation of Drug Therapy for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children

更新时间：2022-11-03

- Rapid Evidence-Based Evaluation of Drug Therapy for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children
- Vol. 26, Issue 4, Pages: 18-23(2020)
- 作者机构：
  
  1. 北京大学第三医院,北京,100191
  2. 北京大学医学部药物评价中心,北京,100191
  3. 北京大学药学院药事管理与临床药学系,北京,100191
- 作者简介：
- 基金信息：
- DOI：10.13407/ j.cnki.jpp.1672.108X.2020.04.007
  CLC：
- Published：2020，
扫描看全文
Zhou Pengxiang, Zhou Wei, Liu Ling, et al. Rapid Evidence-Based Evaluation of Drug Therapy for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. [J]. 26(4):18-23(2020)
DOI：

Zhou Pengxiang, Zhou Wei, Liu Ling, et al. Rapid Evidence-Based Evaluation of Drug Therapy for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. [J]. 26(4):18-23(2020) DOI： 10.13407/ j.cnki.jpp.1672.108X.2020.04.007.

摘要

目的：采用循证评价和文献综述的方法，总结和分析目前已发表的儿童SARS-CoV-2感染病例、临床实践指南或专家共识以及儿童SARS/MERS感染药物治疗经验，以期为儿童SARS-CoV-2感染药物治疗方案的制定提供循证依据。方法：系统检索PubMed、Embase、the Cochrane Library、CNKI（含新型冠状病毒肺炎专题知识库）、WanFang Data、SinoMed和中华医学会杂志社（新型冠状病毒防控和诊治专栏）等数据库，根据文献研究特点和需要，设置快速检索策略和时限，对符合纳入标准的研究中的药物治疗部分进行总结和描述性分析。结果：最终纳入11篇报告儿童病例的研究或综述（共196例患儿）和8篇指南，对儿童SARS/MERS感染的药物治疗经验进行综述。截止目前，已报道儿童感染病例的药物治疗方案基本依从儿童SARS-CoV-2感染指南推荐，且与既往发表的儿童SARS/MERS的药物治疗经验基本一致，α-干扰素为最常应用和最多推荐的抗病毒药物，其他抗病毒药物的应用多参考成人用法，有效性和安全性需要临床研究进一步予以证实；糖皮质激素和人免疫球蛋白在重症患儿中的应用尚存在争议，需权衡利弊谨慎使用；抗菌药物治疗需严格把握用药指征；其他治疗（如中医药）同样需要更多数据予以支持。结论：目前对于儿童SARS-CoV-2感染，尚无确证有效的药物治疗方案，这与儿童SARS/MERS的药物治疗经验基本一致，药物治疗方案的制定仍需进一步临床试验数据和用药经验总结的支持。

Abstract

Objective: To summarize and analyze the currently published literature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Children

clinical practice guidelines or expert consensus and experience in drug therapy of SARS/MERS infection in children based on evidence-based evaluation and literature review

so as to provide evidence-based basis for the formulation of drug therapy for children with SARS-CoV-2 infection. Methods: PubMed

EMBase

the Cochrane Library

CNKI (including the special database of corona virus disease 2019)

WanFang Data

SinoMed

and the Chinese Medical Association Journal (column of prevention

control and diagnosis of SARS-CoV-2) were systematically retrieved. According to the characteristics and needs of the literature research

the rapid retrieval strategy and time limit were set up to summarize and descriptively analyze the drug therapy that met the inclusion criteria. Results: Totally 11 literature and pediatric cases reports (196 children) and 8 pediatric clinical practice guidelines or expert consensus were included. The medical therapeutic experience of children with SARS/MERS infection were reviewed. Up to now

the drug therapy regimens for reported cases were basically complied with the recommendation of SARS-CoV-2 infection guidelines for children and consistent with the previously published drug therapy experience for children with SARS/MERS. Alpha-interferon was the most commonly used and recommended. The use of other antiviral drugs mostly referred to the drug use of adults

the effectiveness and safety need to be further confirmed by clinical studies. The application of glucocorticoids and human immunoglobulins in children with severe infection was still controversial

and the pros and cons need to be weighed and used with caution. The indication of antibiotics treatment should be strictly controlled. Other treatments

such as traditional Chinese medicine

also need more supportive data. Conclusion: At present

for children with SARS-CoV-2 infection

there is no confirmed effective drug therapy regimens

which is basically consistent with the treatment experience of SARS/MERS. Development of drug therapy regimens for SARS-CoV-2 infection in children still requires further clinical trial data and experience.

关键词

新型冠状病毒SARS-CoV-2儿童药物治疗指南

Keywords

corona virus disease 2019severe acute respiratory syndrome coronavirus 2childrenrug therapyguideline

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Characteristics and Drug Therapy of 4 Cases of Children with Corona Virus Disease 2019

Analysis of 36 Cases of Drug Poisoning in Children in a Grade III, Level A General Hospital andConsideration on Pharmaceutical Care

Application of Dexmedetomidine Combined with Hydromorphone Nasal Drip in Sedation of Mother-InfantSeparation before Adenoidectomy

Sirolimus in the Treatment of 5 Cases of Blue Rubber Bleb Nevus Syndrome in Children and Literature Review

Systematic Review on Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metabolic Disordersin Children

Related Author

Ji Taiyang

Chen Quanjing

Chen Fuchao

Huang Linjie

Chen Shaojun

Lyu Mingzhu

Su Xiaofang

Wang Peng

Related Institution

Dongfeng Hospital Affiliated to Hubei University of Medicine

The Second People’ s Hospital of Anhui Wuhu, Anhui Wuhu

Jiangsu Taizhou People’s Hospital, Jiangsu Taizhou

Children’s Hospital Affiliated to Zhengzhou University,Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou Key Laboratory of Children’s Digestive Diseases

Kunming Children’s Hospital / Children’s Hospital of Kunming Medical University, Kunming

⁰